RESUMEN
SLE is a complex systemic disease which probably has a multifactorial genesis. The basis alteration takes the form of a severe immunoregulation disorders. From an epidemiological point of view, there are no certain links with country of origin or race; knowledge of the disease's etiology is equally limited. Clinical symptoms are widely variable according to the prevalent organ or apparatus pathology. The symptomatology of SLE is in fact highly polymorphous thus making it complex and sometimes difficult to diagnose. From a prognostic point of view, over recent years the future of these patients has appeared brighter than in the past. The current therapeutic approach uses a number of measures which can be used in combination or sequentially. It is precisely this varying combination of therapies that has led to a marked prolongation of survival and long disease-free periods.
Asunto(s)
Lupus Eritematoso Sistémico , Humanos , Lupus Eritematoso Sistémico/diagnóstico , Lupus Eritematoso Sistémico/inmunología , Lupus Eritematoso Sistémico/terapiaRESUMEN
The Authors have controlled the colony growth in coltures from peripheral leukocytes of normal subjects and from patients with CML and AML. The cultures were prepared on double agar layer in basal conditions and after adding flurbiprofen and/or cortisol and/or testosterone. The exam of the plates has shown a light similar stimulating activity on the growth of all substances separately considered, with and evidence ability of flurbiprofen of potentiate the action of the two hormones, both in coltures from normal and leukemic peripheral leukocyte CFU-GM.
Asunto(s)
Flurbiprofeno/farmacología , Células Madre Hematopoyéticas/efectos de los fármacos , Hidrocortisona/farmacología , Leucemia/sangre , Leucocitos/efectos de los fármacos , Prostaglandinas E/antagonistas & inhibidores , Testosterona/farmacología , Células Cultivadas , HumanosRESUMEN
Penbutolol has proved particularly effective and suitable for the treatment, even on a long-term basis, of recently developed hypertension, especially in its hyperkinetic forms. The drug produces minimal side effects, is well tolerated and gives an early therapeutic response. In addition penbutolol does not cause any significant alterations in the biohumoral parameters of the patients treated and is ideal for combination with dihydralazine, reserpine and dihydrochlorotiazide in the treatment of more stubborn cases, making it possible to reduce the doses of the other drugs without causing bradycardia.